Prentiss Smith & Co. Inc. lessened its holdings in GlycoMimetics Inc (NASDAQ:GLYC) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,000 shares of the biotechnology company’s stock after selling 3,000 shares during the period. Prentiss Smith & Co. Inc.’s holdings in GlycoMimetics were worth $118,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of GLYC. SG Americas Securities LLC purchased a new stake in GlycoMimetics in the 4th quarter valued at about $103,000. First Mercantile Trust Co. increased its stake in GlycoMimetics by 26.6% in the 4th quarter. First Mercantile Trust Co. now owns 11,726 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 2,466 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in GlycoMimetics in the 3rd quarter valued at about $173,000. Virtu Financial LLC purchased a new stake in GlycoMimetics in the 4th quarter valued at about $210,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in GlycoMimetics in the 2nd quarter valued at about $146,000. Institutional investors own 97.44% of the company’s stock.
In other news, SVP Helen M. Thackray sold 2,000 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $15.01, for a total transaction of $30,020.00. Following the completion of the transaction, the senior vice president now directly owns 148,615 shares of the company’s stock, valued at approximately $2,230,711.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 43.80% of the stock is owned by corporate insiders.
Shares of GlycoMimetics Inc (NASDAQ:GLYC) opened at $23.16 on Wednesday. GlycoMimetics Inc has a one year low of $3.82 and a one year high of $26.05.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics Inc (NASDAQ:GLYC).
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.